Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

Nakayama, Masahiro; Tabuchi, Keiji; Hara, Akira

doi:10.1002/hed.23823

Cited by 50 publications

(59 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15–19] Published data also show that elevated CRP values and neutrophil to lymphocyte ratios have adverse effects on the survival of patients with localized head and neck cancer, treated with curative intent. [25–30] The calculated cutoff values for leukocytes and CRP in this study were 9.25 G/L and 8.5 mg/L respectively, which is close to the upper normal limits. High CRP and high leukocytes, which may reflect inflammation caused by the tumor as well as individual comorbidities, were also poor prognostic factors for patients in this cohort.…”

Section: Discussionsupporting

confidence: 73%

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

et al. 2017

View full text Add to dashboard Cite

Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and clinical parameters may help improve the prognostication in this patient group. This retrospective monocenter analysis includes 128 patients with recurrent or metastatic SCCHN treated with cetuximab alone or in combination with polychemotherapy as first line therapy. Factors with independent prognostic power in the multivariate analysis were used to build up a score separating patient groups with different survival. Patients had a median age of 61 years and 103 patients were treated with polychemotherapy plus cetuximab. An ECOG score above 1, high CRP and leukocyte levels, less intensive treatment and a time below 12 months from primary diagnosis to relapse remained as independent negative prognostic factors in multivariate analysis.Patients with 0 to 1 risk factors had a median OS of 13.6 months compared to a median OS of less than one month for patients 4 to 5 risk factors (p<0.001). This study identifies 5 clinical and serum values that influence survival of patients with recurrent or metastatic SCCHN treated with cetuximab. By combining these factors to create a score for OS, it is possible to distinguish a group of patients with significantly improved survival and define those most likely to have no benefit from cetuximab treatment.

show abstract

Section: Discussionsupporting

confidence: 73%

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Cancer cachexia is caused by activated cytokines and is commonly found in patients with cancer . Several studies have identified the Glasgow prognostic score as a significant prognostic score for many tumor types, including head and neck cancers . Our study also demonstrated that a higher pretreatment Glasgow prognostic score can be correlated with advanced tumor stage and that the Glasgow prognostic score is also an independent prognostic parameter.…”

Section: Discussionsupporting

confidence: 70%

Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Furthermore, our findings also demonstrated that a higher pretreatment GPS was associated with poor disease-free survival (DFS) and OS, which is in accordance with a previous study reported by Nakayama et al . (8). Since the GPS can reflect the degree of cachexia and malnutrition (6), and considering that the post-CCRT GPS declined in most patients in our study, we further analyzed the prognostic role of post-CCRT GPS as a biomarker for the follow-up of the patients’ nutritional status and found that the post-CCRT GPS level was an independent prognostic factor in the multivariate analysis, rather than the pre-CCRT GPS ( Table 2 ), implying that poor nutrition after CCRT can predict survival.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, it is reasonable to use the GPS as a biomarker for malnutrition surveillance. Further, the pretreatment GPS has been shown to be a prognostic factor in head and neck cancer (8), with the overall survival (OS) and recurrence-free survival (RFS) being higher when the GPS was low. …”

Section: Introductionmentioning

confidence: 99%

Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer

Chang¹,

Wang²,

Chen³

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective This study aims to evaluate the impact and potential prognostic roles of the pre- and post-treatment Glasgow prognostic score (GPS) and the change thereof in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy (CCRT).Methods We collected GPS and clinicopathological data of 139 stage III, IVA, and IVB head and neck cancer patients who underwent CCRT between 2008 and 2011. Their GPSs pre- and post-CCRT and the change thereof were analyzed for correlations with recurrence and survival. Results The GPS changed in 72 (51.8%) patients, with worse scores observed post-CCRT in 65 (90.3%) of the GPS changed patients. Patients in the improved GPS group showed a tendency toward better survival. From the multivariate analysis, the post-CCRT GPS level was an independent prognostic factor in addition to tumor stage. Conclusions After CCRT, a high GPS was revealed to be an important predictor of survival for advanced head and neck cancer.

show abstract

Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

Abstract: Our results suggest that the mGPS is useful for predicting outcome in patients with advanced head and neck cancer and should be included in their routine clinical assessment.

Cited by 50 publications

References 34 publications

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy

Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer

Contact Info

Product

Resources

About